The activity and expression of NTPDase is altered in lymphocytes of multiple sclerosis patients

Clinica Chimica Acta

Volumn 411, Issue 3-4, 2010, Pages 210-214

  Spanevello, Roselia M ^a   Mazzanti, Cinthia M ^b   Schmatz, Roberta ^b   Thomé, Gustavo ^b   Bagatini, Margarete ^b   Correa, Maisa ^b   Rosa, Cintia ^b   Stefanello, Naiara ^b   Bellé, Luziane Potrich ^b   Moretto, Maria B ^b   Oliveira, Liliane ^c   Morsch, Vera M ^b   Schetinger, Maria R C ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^c Hospital Universitario   (Brazil)

Author keywords

Adenosine deaminase; Lymphocytes; Multiple sclerosis; NTPDase

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE TRIPHOSPHATE; BETA INTERFERON; CD39 ANTIGEN; CLONAZEPAM; MYELIN PROTEIN; PARACETAMOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; MULTIPLE SCLEROSIS; NUCLEIC ACID ANALYSIS; ONSET AGE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; TREATMENT OUTCOME;

ADENOSINE DEAMINASE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADULT; AGED; ANTIGENS, CD; APYRASE; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE;

EID: 72649101947     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.11.005     Document Type: Article

References (42)

1. Winquist R., Kwong A., Ramachandran R., and Jain J. The complex etiology of multiple sclerosis. Biochem Pharmacol 74 (2007) 1321-1329
2. Trapp B., and Nave K. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu Rev Neurosci 31 (2008) 247-269
3. Peterson L., and Fujinami R. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 184 (2006) 37-44
4. Franciotto D., Salvetti M., Lolli F., Serafini B., and Aloisi F. B cells and multiple sclerosis. Lancet Neurol 7 (2008) 852-858
5. Bours M., Swennen E., Di Virgilio F., Cronstein B., and Dagnelie P. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112 (2006) 358-404
6. Di Virgilio F. Purinergic signalling in the immune system. A brief update. Purinergic Signal 3 (2007) 1-3
7. Langston H., Ke Y., Gewirtz A., Dombrowski K., and Kapp J. Secretion of IL-2 and IFN-y, but not IL-4, by antigen-specific T cells requires extracellular ATP. J Immunol 170 (2003) 2962-2970
8. Linden J. New insights into the regulation of inflammation by adenosine. J Clin Invest 116 (2006) 1835-1837
9. Deaglio S., Dwyer K., Gao W., et al. Adenosine generation catalysed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204 (2007) 1257-1265
10. Gessi S., Varani K., Merighi S., et al. Adenosine and lymphocyte regulation. Purinergic Signal 3 (2007) 109-116
11. Robson S., Sévigny J., and Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2 (2006) 409-430
12. Zimmermann H., Mishra S., Shukla V., et al. Ecto-nucleotidases, molecular properties and functional impact. An R Acad Nac Farm 73 (2007) 537-566
13. Yegutkin G. Nucleotide and nucleoside converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 1783 (2008) 673-694
14. Pulte E., Broekman M., Olson K., et al. CD39/NTPDase-1 activity and expression in normal leucocytes. Thromb Res 121 (2007) 309-317
15. Dwyer K., Deaglio S., Gao W., Friedman D., Strom T., and Robson S. CD39 and control of cellular immune responses. Purinergic Signal 3 (2007) 171-180
16. Leal D., Streher C., Bertoncheli C., et al. HIV infection is associated with increased NTPDase activity correlates with CD39-positive lymphocytes. Biochim Biophys Acta 1746 (2005) 129-134
17. Franco R., Casadó V., Ciruela F., et al. Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol 52 (1997) 283-292
18. Codero O., Salgado F., Fernández-Alonso C., et al. Cytokines regulate membrane adenosine deaminase on human activated lymphocytes. J Leukoc Biol 70 (2001) 920-930
19. Aldrich M., Blackburn M., and Kellems R. The importance of adenosine deaminase for lymphocyte development and function. Biochem Biophys Res 272 (2000) 311-335
20. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
21. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest 97 (1968) 77-89
22. Leal D., Streher C., Neu T., et al. Characterization of NTPDase (NTPDase 1: ecto-apyrase; ecto-diphosphohydrolase; CD39; E.C. 3.6.1.5) activity in human lymphocytes. Biochim Biophys Acta 1721 (2005) 9-11
23. 2+-ATPase activity. Anal Biochem 157 (1986) 375-378
24. Giusti G., and Gakis C. Temperature conversion factors, activation energy, relative substrate specificity and optimum pH of adenosine deaminase from human serum and tissues. Enzyme 12 (1971) 417-425
25. Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
26. Munafo A., Lugan-Trinchard I., Nguyen T., and Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta 1a after intramuscular and subcutaneous administration. Eur J Neurol 5 (1998) 187-193
27. Buchwalder P., Buclin T., Trinchard I., Munafo A., and Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-β in healthy volunteers. J Interferon Cytokine Res 20 (2000) 857-866
28. Crevoisier C., Delisle M.C., Joseph I., and Foletti G. Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. Eur Neurol 49 (2003) 173-177
29. Wang A., Sun J., Feng H., Gao S., and He Z. Simultaneous determination of paracetamol and caffeine in human plasma by LC-ESI-MS. Chromatografia 67 (2007) 281-285
30. Fox R., Bethoux F., Goldman M., and Cohen J. Multiple sclerosis: advances in understanding, diagnosing and treating the underlying disease. Clin J Med 73 (2006) 91-102
31. Lassmann H. Mechanisms of inflammation induced tissue injury in multiple sclerosis. J Neurol Sci 274 (2008) 45-47
32. Dhib-Jalbut S., Arnold D., Cleveland D., et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol 176 (2006) 198-215
33. Hitoglu S., Hatzistilianou M., Gougoustamou D., Athanassiadou F., Kotsis A., and Catriu D. Adenosine deaminase activity and its isoenzyme pattern in patients with juvenile rheumatoid arthritis and systemic lupus erythemathosus. Clin Rheumatol 20 (2001) 411-416
34. Vivekanandhan S., Soundararajan C., Tripathi M., and Maheshwari M. Adenosine deaminase and 5′-nucleotidase activities in peripheral blood T cells of multiple sclerosis patients. Neurochem Res 30 (2005) 453-456
35. Poursharifi P., Saghiri R., Ebrahimi-Rad M., et al. Adenosina deaminase in patients with primary immunodeficiency syndromes: The analysis of serum ADA1 and ADA2 activities. Clin Biochem 42 (2009) 1438-1443
36. Trautmann A. Extracellular ATP in immune system: more than a just a danger signal. Sci Signal 2 (2009) 1-3
37. Kannan S. E-NTPDase/NTPDase: potential role as a regulatory element in inflammation. Med Hypothesis 58 (2002) 527-528
38. Haskó G., Kuhel D., Chen J., et al. Adenosine inhibits IL-12 and TFN-production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 14 (2000) 2065-2074
39. 2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J 22 (2008) 3491-3499
40. ®) therapy. Mult Scler 8 (2002) 15-18
41. Tourbah A., and Lyon-Caen O. Interferons in multiple sclerosis: ten years' experience. Biochemie 89 (2007) 899-902
42. Toosy A., and Thompson A. Multiple sclerosis - the disease and its treatment. Pharm J 264 (2000) 694-700